Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men.

Weber JP, Walsh PC, Peters CA, Spivak JL

American journal of hematology1 Mar 1991Cited by 43 (Europe PMC)

PMID1705094DOI10.1002/ajh.2830360306PepBankPUB-01705094

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialMechanism
In men treated with nafarelin, mean testosterone decreased from 4.35 +/- 1.05 ng/ml to castrate levels by 6 months.
In plain wordsIn men treated with nafarelin, testosterone decreased to castrate levels by 6 months.
Peptide
Nafarelin
Outcome
DecreaseTestosterone during treatment
Study
n = 7
Comparator
Pretreatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Baseline testosterone
4.35 ng/ml
mean
Baseline testosterone SD
1.05 ng/ml
pretreatment
Source sentences
Summary
The mean serum testosterone level was 4.35 +/- 1.05 ng/ml initially and it decreased to castrate levels in all patients by 6 months.
2 context sentences(design, population, supporting numbers)
Summary · context
No significant inhibition of burst-forming unit-erythroid (BFU-E) or colony-forming unit-granulocyte macrophage (CFU-GM) was observed at the serum level of nafarelin acetate obtainable in vivo.
Summary · context
To examine the role of testosterone in the maintenance of hemoglobin levels, we studied the effect of reversible androgen deprivation on hemoglobin, serum immunoreactive erythropoietin, and serum testosterone in seven men treated with a luteinizing hormone-releasing factor (LHRH) agonist for 6 month…
Report a problemFND-0170509401
02HumanNon-randomized trialMechanism
In men previously treated with nafarelin, testosterone increased rapidly after cessation and reached a normal mean concentration by 12 months.
In plain wordsIn men previously treated with nafarelin, testosterone increased rapidly after cessation and reached a normal mean concentration by 12 months.
Peptide
Nafarelin
Outcome
IncreaseTestosterone after treatment cessation
Study
n = 7
Comparator
End of treatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
After stopping therapy, there was a rapid increase in serum testosterone such that by 12 months the mean concentration was normal.
2 context sentences(design, population, supporting numbers)
Summary · context
No significant inhibition of burst-forming unit-erythroid (BFU-E) or colony-forming unit-granulocyte macrophage (CFU-GM) was observed at the serum level of nafarelin acetate obtainable in vivo.
Summary · context
To examine the role of testosterone in the maintenance of hemoglobin levels, we studied the effect of reversible androgen deprivation on hemoglobin, serum immunoreactive erythropoietin, and serum testosterone in seven men treated with a luteinizing hormone-releasing factor (LHRH) agonist for 6 month…
Report a problemFND-0170509402
03HumanNon-randomized trialSafety outcome
In men treated with nafarelin, hemoglobin decreased from 15.2 +/- 0.9 to 14.1 +/- 0.4 g/dl after 6 months (P less than 0.05).
In plain wordsIn men treated with nafarelin, hemoglobin decreased after 6 months.
Peptide
Nafarelin
Outcome
DecreaseHemoglobin during treatment
Study
n = 7
Comparator
Pretreatment
Outcome group
Blood cell measures · Whole body
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Hemoglobin
15.2 g/dl
pretreatment mean
Hemoglobin SD
0.9 g/dl
pretreatment
Hemoglobin
14.1 g/dl
6 months mean
Hemoglobin SD
0.4 g/dl
6 months
Source sentences
Summary
The pretreatment hemoglobin was 15.2 +/- 0.9 g/dl (mean +/- SD); after 6 months of androgen deprivation it had fallen to 14.1 +/- 0.4 g/dl (P less than 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
No significant inhibition of burst-forming unit-erythroid (BFU-E) or colony-forming unit-granulocyte macrophage (CFU-GM) was observed at the serum level of nafarelin acetate obtainable in vivo.
Summary · context
To examine the role of testosterone in the maintenance of hemoglobin levels, we studied the effect of reversible androgen deprivation on hemoglobin, serum immunoreactive erythropoietin, and serum testosterone in seven men treated with a luteinizing hormone-releasing factor (LHRH) agonist for 6 month…
Report a problemFND-0170509403
04HumanNon-randomized trialSafety outcome
In men previously treated with nafarelin, hemoglobin rose to pretreatment levels 6 months after therapy stopped.
In plain wordsIn men previously treated with nafarelin, hemoglobin returned to pretreatment levels 6 months after therapy stopped.
Peptide
Nafarelin
Outcome
IncreaseHemoglobin after treatment cessation
Study
n = 7
Comparator
End of treatment
Outcome group
Blood cell measures · Whole body
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Six months after stopping therapy, the hemoglobin rose to pre-treatment levels.
2 context sentences(design, population, supporting numbers)
Summary · context
No significant inhibition of burst-forming unit-erythroid (BFU-E) or colony-forming unit-granulocyte macrophage (CFU-GM) was observed at the serum level of nafarelin acetate obtainable in vivo.
Summary · context
To examine the role of testosterone in the maintenance of hemoglobin levels, we studied the effect of reversible androgen deprivation on hemoglobin, serum immunoreactive erythropoietin, and serum testosterone in seven men treated with a luteinizing hormone-releasing factor (LHRH) agonist for 6 month…
Report a problemFND-0170509404
05HumanNon-randomized trialMechanism
In men treated with nafarelin, erythropoietin did not change significantly during or after androgen deprivation from baseline 9.5 +/- 4.6 mu/ml.
In plain wordsIn men treated with nafarelin, erythropoietin did not change significantly during or after androgen deprivation.
Peptide
Nafarelin
Outcome
No significant changeImmunoreactive erythropoietin
Study
n = 7
Comparator
Pretreatment
Outcome group
Blood cell measures · Whole body
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Erythropoietin
9.5 mu/ml
pretreatment mean
Erythropoietin SD
4.6 mu/ml
pretreatment
Source sentences
Summary
Before treatment, serum immunoreactive erythropoietin was 9.5 +/- 4.6 mu/ml (mean +/- SD) and did not change significantly during or after the 6 month period of androgen deprivation.
2 context sentences(design, population, supporting numbers)
Summary · context
No significant inhibition of burst-forming unit-erythroid (BFU-E) or colony-forming unit-granulocyte macrophage (CFU-GM) was observed at the serum level of nafarelin acetate obtainable in vivo.
Summary · context
To examine the role of testosterone in the maintenance of hemoglobin levels, we studied the effect of reversible androgen deprivation on hemoglobin, serum immunoreactive erythropoietin, and serum testosterone in seven men treated with a luteinizing hormone-releasing factor (LHRH) agonist for 6 month…
Report a problemFND-0170509405
06LabIn vitro (cells)Mechanism
In lab tests, nafarelin at serum concentrations obtainable in vivo did not significantly inhibit BFU-E.
In plain wordsIn lab tests, nafarelin at concentrations obtainable in blood did not significantly inhibit erythroid colony formation.
Peptide
Nafarelin
Outcome
No significant changeBFU-E inhibition
Study
n: not reported in source
Erythroid colony assay
Outcome group
Blood cell measures · Whole body
Studied dose
Dose not stated
Source sentences
Summary
No significant inhibition of burst-forming unit-erythroid (BFU-E) or colony-forming unit-granulocyte macrophage (CFU-GM) was observed at the serum level of nafarelin acetate obtainable in vivo.
1 context sentence(design, population, supporting numbers)
Summary · context
To examine the role of testosterone in the maintenance of hemoglobin levels, we studied the effect of reversible androgen deprivation on hemoglobin, serum immunoreactive erythropoietin, and serum testosterone in seven men treated with a luteinizing hormone-releasing factor (LHRH) agonist for 6 month…
Report a problemFND-0170509406
07LabIn vitro (cells)Mechanism
In lab tests, nafarelin at serum concentrations obtainable in vivo did not significantly inhibit CFU-GM.
In plain wordsIn lab tests, nafarelin at concentrations obtainable in blood did not significantly inhibit granulocyte-macrophage colony formation.
Peptide
Nafarelin
Outcome
No significant changeCFU-GM inhibition
Study
n: not reported in source
Granulocyte-macrophage colony assay
Outcome group
Blood cell measures · Whole body
Studied dose
Dose not stated
Source sentences
Summary
No significant inhibition of burst-forming unit-erythroid (BFU-E) or colony-forming unit-granulocyte macrophage (CFU-GM) was observed at the serum level of nafarelin acetate obtainable in vivo.
1 context sentence(design, population, supporting numbers)
Summary · context
To examine the role of testosterone in the maintenance of hemoglobin levels, we studied the effect of reversible androgen deprivation on hemoglobin, serum immunoreactive erythropoietin, and serum testosterone in seven men treated with a luteinizing hormone-releasing factor (LHRH) agonist for 6 month…
Report a problemFND-0170509407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.